<DOC>
	<DOCNO>NCT00189319</DOCNO>
	<brief_summary>The purpose study evaluate management paroxysmal atrial fibrillation control release flecainide patient 's quality life .</brief_summary>
	<brief_title>To Evaluate Impact Oral Flecainide Quality Life Patients With Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<criteria>In sinus rhythm treatment initiation Experienced symptomatic AF episodes Left ventricular ejection fraction least 40 % Females child bear potential must use reliable method contraception Intolerance and/or failure previous therapy flecainide immediate release Currently receive &gt; 200mg/day flecainide immediate release Severe symptom episodes arrhythmia History cardiac conditions/abnormalities Heart surgery within last 2 month Renal failure Pregnant lactating female Significant extra cardiac systemic disease Abnormal electrolyte level Receiving define cardiac and/or treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Tambocor</keyword>
	<keyword>Paroxysmal Atrial Fibrillation</keyword>
	<keyword>Quality Life</keyword>
</DOC>